Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 16515
Country/Region: Zimbabwe
Year: 2016
Main Partner: University of Washington
Main Partner Program: I-TECH
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $13,029,528 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $335,289
Care: Pediatric Care and Support (PDCS) $438,489
Testing: HIV Testing and Counseling (HVCT) $3,256,262
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $433,371
Treatment: Adult Treatment (HTXS) $7,476,333
Treatment: Pediatric Treatment (PDTX) $1,089,784
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 765
HTS_TST Age/sex: <1 2017 1,525
HTS_TST Age/sex: 1-9 2017 8,614
HTS_TST Age/sex: 1-9 2017 4,500
HTS_TST Age/sex: 10-14 Female 2017 733
HTS_TST Age/sex: 10-14 Female 2017 540
HTS_TST Age/sex: 10-14 Male 2017 598
HTS_TST Age/sex: 10-14 Male 2017 444
HTS_TST Age/sex: 15-19 Female 2017 1,086
HTS_TST Age/sex: 15-19 Female 2017 801
HTS_TST Age/sex: 15-19 Male 2017 566
HTS_TST Age/sex: 15-19 Male 2017 416
HTS_TST Age/sex: 20-24 Female 2017 3,394
HTS_TST Age/sex: 20-24 Female 2017 2,501
HTS_TST Age/sex: 20-24 Male 2017 958
HTS_TST Age/sex: 20-24 Male 2017 705
HTS_TST Age/sex: 25-49 Female 2017 27,541
HTS_TST Age/sex: 25-49 Female 2017 20,300
HTS_TST Age/sex: 25-49 Male 2017 15,652
HTS_TST Age/sex: 25-49 Male 2017 11,539
HTS_TST Age/sex: 50+ Female 2017 3,594
HTS_TST Age/sex: 50+ Female 2017 2,650
HTS_TST Age/sex: 50+ Male 2017 3,459
HTS_TST Age/sex: 50+ Male 2017 2,549
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 36,868
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 36,676
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 35,338
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 37,031
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 232,084
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 326,282
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 131,924
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 172,662
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 636,724
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 488,043
HTS_TST Service Delivery Point (Facility): Inpatient 2017 37,748
HTS_TST Service Delivery Point (Facility): Inpatient 2017 47,661
HTS_TST Service Delivery Point (Facility): Outpatient 2017 295,692
HTS_TST Service Delivery Point (Facility): Outpatient 2017 428,996
HTS_TST Service Delivery Point (Facility): Pediatric 2017 6,310
HTS_TST Service Delivery Point (Facility): Pediatric 2017 69,250
HTS_TST Service Delivery Point (Facility): PMTCT 2017 15,372
HTS_TST Service Delivery Point (Facility): PMTCT 2017 88,452
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 15,152
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,211
HTS_TST Service Delivery Point (Facility): VMMC 2017 308
HTS_TST Sum of Age/Sex disaggregates 2017 57,581
HTS_TST Sum of Age/Sex disaggregates 2017 42,445
HTS_TST Sum of Aggregated Age/Sex <15 2017 72,206
HTS_TST Sum of Aggregated Age/Sex <15 2017 73,707
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 364,008
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 498,944
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 436,214
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 572,651
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 105
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 47
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 40
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 85
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 80
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 96
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 48
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 41
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 248
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 300
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 85
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 70
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,012
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,434
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,383
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,145
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 263
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 319
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 303
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 253
HTS_TST_POS Test Result by Age: Positive: <1 2017 28
HTS_TST_POS Test Result by Age: Positive: <1 2017 19
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 293
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 137
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,201
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 2,373
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 2,110
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 2,280
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 22,222
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 34,500
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 12,604
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 18,070
PMTCT_ART Already on ART at beginning of current pregnancy 2017 8,510
PMTCT_ART New on ART 2017 6,416
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 92,063
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 11,343
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3,575
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 153
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 208
PMTCT_EID Sum of Infant Age disaggregates 2017 14,918
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 4,548
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 9,177
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 27,464
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 45,776
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 4,564
PMTCT_STAT By: Known positives at entry 2017 8,753
PMTCT_STAT By: Number of new positives identified 2017 8,644
PMTCT_STAT Number of new ANC and L&D clients 2017 96,976
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 92,063
PMTCT_STAT Required only for DREAMS countries - By known positives: <15 2017 368
PMTCT_STAT Required only for DREAMS countries - By known positives: 15-19 2017 355
PMTCT_STAT Required only for DREAMS countries - By known positives: 20-24 2017 799
PMTCT_STAT Required only for DREAMS countries - By known positives: 25-49 2017 6,132
PMTCT_STAT Required only for DREAMS countries - By known positives: 50+ 2017 1,099
PMTCT_STAT Required only for DREAMS countries - By new positives: <15 2017 357
PMTCT_STAT Required only for DREAMS countries - By new positives: 15-19 2017 355
PMTCT_STAT Required only for DREAMS countries - By new positives: 20-24 2017 789
PMTCT_STAT Required only for DREAMS countries - By new positives: 25-49 2017 6,060
PMTCT_STAT Required only for DREAMS countries - By new positives: 50+ 2017 1,083
PMTCT_STAT Sum of Positives Status disaggregates 2017 17,397
PMTCT_STAT_den Required only for DREAMS countries - Denominator: <15 2017 4,844
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 15-19 2017 9,699
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 20-24 2017 29,094
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 25-49 2017 48,486
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 50+ 2017 4,843
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 44
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,642
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 68
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,217
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 4,957
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 3,970
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 90,312
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 85,794
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 4,516
TB_SCREENDX Screen Results: Screened Positive for TB 2017 92,095
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 11,833
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 11,087
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 214,458
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 126,424
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 363,805
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 149
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,817
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 222
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,077
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 7,255
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 7,405
TX_CURR Age/Sex: <1 2017 78
TX_CURR Age/Sex: <1 2017 8
TX_CURR Age/Sex: <1-9 2017 140
TX_CURR Age/Sex: 1-9 2017 840
TX_CURR Age/Sex: 10-14 Female 2017 297
TX_CURR Age/Sex: 10-14 Female 2017 48
TX_CURR Age/Sex: 10-14 Male 2017 245
TX_CURR Age/Sex: 10-14 Male 2017 40
TX_CURR Age/Sex: 15-19 Female 2017 444
TX_CURR Age/Sex: 15-19 Female 2017 74
TX_CURR Age/Sex: 15-19 Male 2017 231
TX_CURR Age/Sex: 15-19 Male 2017 40
TX_CURR Age/Sex: 20-24 Female 2017 1,381
TX_CURR Age/Sex: 20-24 Female 2017 229
TX_CURR Age/Sex: 20-24 Male 2017 389
TX_CURR Age/Sex: 20-24 Male 2017 65
TX_CURR Age/Sex: 25-49 Female 2017 11,205
TX_CURR Age/Sex: 25-49 Female 2017 1,861
TX_CURR Age/Sex: 25-49 Male 2017 6,375
TX_CURR Age/Sex: 25-49 Male 2017 1,056
TX_CURR Age/Sex: 50+ Female 2017 1,464
TX_CURR Age/Sex: 50+ Female 2017 245
TX_CURR Age/Sex: 50+ Male 2017 1,409
TX_CURR Age/Sex: 50+ Male 2017 234
TX_CURR Aggregated Age/Sex: <15 Female 2017 12,230
TX_CURR Aggregated Age/Sex: <15 Female 2017 8,029
TX_CURR Aggregated Age/Sex: <15 Male 2017 11,896
TX_CURR Aggregated Age/Sex: <15 Male 2017 7,950
TX_CURR Aggregated Age/Sex: 15+ Female 2017 172,884
TX_CURR Aggregated Age/Sex: 15+ Female 2017 32,390
TX_CURR Aggregated Age/Sex: 15+ Male 2017 100,905
TX_CURR Aggregated Age/Sex: 15+ Male 2017 18,736
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 322,273
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 70,723
TX_CURR Sum of age/sex disaggregates 2017 114
TX_CURR Sum of Age/Sex disaggregations 2017 675
TX_CURR Sum of Aggregated Age/Sex <15 2017 24,126
TX_CURR Sum of Aggregated Age/Sex <15 2017 15,979
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 273,789
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 51,126
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 297,915
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 67,105
TX_NEW Aggregated Grouping by Age: <1 2017 36
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 4,439
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,825
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 4,316
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2,756
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 20,656
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 21,098
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 16,321
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 12,628
TX_NEW By Age/Sex: <1 2017 67
TX_NEW By Age/Sex: 1-9 2017 357
TX_NEW By Age/Sex: 1-9 2017 713
TX_NEW By Age/Sex: 10-14 Female 2017 126
TX_NEW By Age/Sex: 10-14 Female 2017 241
TX_NEW By Age/Sex: 10-14 Male 2017 104
TX_NEW By Age/Sex: 10-14 Male 2017 231
TX_NEW By Age/Sex: 15-19 Female 2017 555
TX_NEW By Age/Sex: 15-19 Male 2017 133
TX_NEW By Age/Sex: 15-19 Male 2017 298
TX_NEW By Age/Sex: 20-24 Female 2017 1,851
TX_NEW By Age/Sex: 20-24 Male 2017 223
TX_NEW By Age/Sex: 20-24 Male 2017 551
TX_NEW By Age/Sex: 25-49 Female 2017 13,432
TX_NEW By Age/Sex: 25-49 Male 2017 3,656
TX_NEW By Age/Sex: 25-49 Male 2017 7,351
TX_NEW By Age/Sex: 50+ Female 2017 1,659
TX_NEW By Age/Sex: 50+ Male 2017 808
TX_NEW By Age/Sex: 50+ Male 2017 1,571
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 41,691
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 67,827
TX_NEW Sum of Age/Sex disaggregates 2017 5,050
TX_NEW Sum of Age/Sex disaggregates 2017 27,740
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 45,732
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 39,307
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 80,846
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 56,591
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,627
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,563
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 33,782
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 19,619
TX_PVLS Numerator: Indication: Routine 2017 8,483
TX_PVLS Numerator: Indication: Targeted 2017 33,734
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,327
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,243
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 48,251
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 28,025
TX_PVLS_den Denominator: Indication: Routine 2017 12,131
TX_PVLS_den Denominator: Indication: Targeted 2017 68,715
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 37
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 125
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 65
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 542
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 392
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 90
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 86
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,552
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,481
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29,522
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17,921
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 51,858
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 56,064
TX_RET_den Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 39
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 23
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 138
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 71
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 586
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 424
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 97
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 91
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,672
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,610
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 31,914
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19,373
Cross Cutting Budget Categories and Known Amounts Total: $8,504,013
Human Resources for Health $7,482,593
Gender: Gender Equality $831,420
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Motor Vehicles: Purchased $190,000